Select a medication above to begin.
Symtuza
darunavir/ cobicistat/ emtricitabine/ tenofovir alafenamide
Black Box Warnings .
Hepatitis B Exacerbation
severe acute HBV exacerbations in HBV/HIV co-infected patients when D/C emtricitabine or tenofovir; monitor hepatic function closely for at least several months in HBV/HIV co-infected patients who D/C darunavir/cobicistat/emtricitabine/tenofovir alafenamide; initiate anti-HBV tx if needed
Adult Dosing .
Dosage forms: TAB: 800 mg/150 mg/200 mg/10 mg
HIV infection
- [1 tab PO qd]
- Info: for tx-naive patients or tx-experienced patients without darunavir or tenofovir resistance-associated substitutions; give with food
HIV post-exposure prophylaxis, nonoccupational (off-label)
- [1 tab PO qd]
- Info: give with food; refer to HIV Post-Exposure Prophylaxis, Nonoccupational table
renal dosing
- [see below]
- CrCl <30: avoid use, dose adjustment not possible with fixed-dose combo
- HD: no adjustment, on dialysis days administer after dialysis; consider supplement if next maintenance dose not due right after dialysis; PD: not defined
hepatic dosing
- [see below]
- Child-Pugh Class C: avoid use
Peds Dosing .
- Dosage forms: TAB: 800 mg/150 mg/200 mg/10 mg
HIV infection
- [>40 kg]
- Dose: 1 tab PO qd; Info: for tx-naive patients or tx-experienced patients without darunavir or tenofovir resistance-associated substitutions; give with food
HIV post-exposure prophylaxis, nonoccupational (off-label)
- [>40 kg]
- Dose: 1 tab PO qd; Info: give with food; refer to HIV Post-Exposure Prophylaxis, Nonoccupational table
renal dosing
- [see below]
- CrCl <30: avoid use, dose adjustment not possible with fixed-dose combo
- HD: not defined, consider adult renal dosing for guidance; PD: not defined
hepatic dosing
- [see below]
- Child-Pugh Class C: avoid use